Answers are grounded in this paper and cite their sources.
A 66-year-old woman presented with stage III diffuse large B-cell lymphoma. She was treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy; however, profound cytopenia requiring long-term transfusion subsequently appeared, and acute monocytic leukemia finally developed 10.5 months after the first dose of R-CHOP. G-banding and fluorescence in situ hybridization (FISH) using the MLL break-apart probe determined that the leukemia cells carried t(11;17)(q23;p13).ish t(11;17)(q23;p13)(5'MLL+,3'MLL-;3'MLL+), and reverse-transcriptase polymerase chain reaction and nucleotide sequencing determined that MLL exon 9 fused to GAS7 (growth arrest specific 7) exon 2 in frame. Reevaluation of bone marrow cells by MLL-FISH showed that leukemia cells with the MLL rearrangement had appeared as early as 6.5 months after starting R-CHOP. It remains to be determined whether the MLL-GAS7 rearrangement had occurred before the exposure to chemotherapy or whether this case represented therapy-related leukemia induced by the topoisomerase II inhibitor, doxorubicin. The presence of MLL-GAS7-positive cells in prodromal hematopoietic hypoplasia suggested that these cells exerted a suppressive effect on normal hematopoiesis.
No takes yet. Share an insight, caveat, or question.
Iioka et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: